Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives “Neutral” Rating from Bank of America Corporation
Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “neutral” rating reaffirmed by stock analysts at Bank of America Corporation in a research report issued to clients and investors on Friday, Marketbeat reports. They currently have a $60.00 price objective on the biopharmaceutical company’s stock. Bank of America Corporation’s price objective indicates a potential upside of 21.63% from the stock’s current price.
Several other brokerages have also recently weighed in on ESPR. Jefferies Group LLC initiated coverage on shares of Esperion Therapeutics in a research report on Monday, July 10th. They issued a “hold” rating and a $55.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $60.00 price target (up previously from $45.00) on shares of Esperion Therapeutics in a research report on Monday, June 26th. UBS AG reaffirmed a “buy” rating and issued a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Citigroup Inc. reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Finally, Deutsche Bank AG initiated coverage on shares of Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.51.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up 2.47% on Friday, hitting $49.33. The stock had a trading volume of 937,292 shares. The company has a 50 day moving average price of $47.09 and a 200-day moving average price of $35.27. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38. The stock’s market cap is $1.27 billion.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.67) by $0.25. During the same period in the previous year, the firm earned ($0.62) EPS. On average, equities research analysts anticipate that Esperion Therapeutics will post ($7.29) earnings per share for the current year.
A number of large investors have recently bought and sold shares of ESPR. Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $162,000. Aperio Group LLC purchased a new stake in Esperion Therapeutics during the second quarter worth approximately $249,000. Princeton Alpha Management LP purchased a new stake in Esperion Therapeutics during the first quarter worth approximately $205,000. Finally, Bank of Montreal Can boosted its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. 85.20% of the stock is owned by institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.